Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: A randomized trial

Journal of Infectious Diseases

Volumn 203, Issue 1, 2011, Pages 109-116

  Ursing, Johan ^a,b   Kofoed, Poul Erik ^a,e   Rodrigues, Amabelia ^a   Blessborn, Daniel ^c   Thoft Nielsen, Rikke ^a   Björkman, Anders ^b   Rombo, Lars ^b,c,d  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c DALARNA UNIVERSITY   (Sweden)

^d Mälarsjukhuset ^*  (Sweden)

^e KOLDING HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; QUININE;

ADOLESCENT; AGITATION; ANEMIA; ARTICLE; ASTHENIA; CHILD; CHOLERA; CLINICAL FEATURE; CLINICAL TRIAL; CONVULSION; DELIRIUM; DRUG EFFICACY; DRUG TOLERABILITY; FACE EDEMA; FEMALE; FEVER; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RESISTANCE; GUINEA-BISSAU; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTIDRUG RESISTANCE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; AMINO ACID SUBSTITUTION; ANTIMALARIALS; ARTEMISININS; BLOOD CHEMICAL ANALYSIS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA, PROTOZOAN; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; GUINEA-BISSAU; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MEMBRANE TRANSPORT PROTEINS; MUTATION, MISSENSE; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTOZOAN PROTEINS; TREATMENT OUTCOME;

EID: 79851487308     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq001     Document Type: Article

References (40)

1. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2:209-18. (Pubitemid 34464751)
2. WHO. World malaria report. World Health Organization. 2009.
3. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619-20.
4. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67.
5. Lim P, Alker AP, Khim N, et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J 2009; 8:11.
6. Price RN, Uhlemann AC, van Vugt M, et al. Molecular and pharmacological determinants of the therapeutic response to artemetherlumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42:1570-77.
7. Achan J, Tibenderana JK, Kyabayinze D, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 2009; 339:b2763.
8. Ursing J, Kofoed PE, Rodrigues A, Rombo L, Gil JP. Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau. Am J Trop Med Hyg 2007; 76:844-8. (Pubitemid 351627666)
9. Ursing J, Kofoed PE, Rodrigues A, Rombo L. No seasonal accumulation of resistant P. falciparum when high-dose chloroquine is used. PLoS One 2009; 4:e6866..
10. Ursing J, Schmidt BA, Lebbad M, et al. Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2005 in Guinea-Bissau: an effect of high chloroquine dosage? Infect Genet Evol 2007; 7:555-61.
11. Kofoed PE, Lopez F, Johansson P, et al. Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau. Am J Trop Med Hyg 2002; 67:28-31. (Pubitemid 35034316)
12. Kofoed PE, Ursing J, Poulsen A, et al. Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations. Trans R Soc Trop Med Hyg 2007; 101:231-8. (Pubitemid 46043055)
13. Ursing J, Kofoed PE, Rodrigues A, Bergqvist Y, Rombo L. Chloroquine is grossly overdosed and overused but well tolerated in Guinea-bissau. Antimicrob Agents Chemother 2009; 53:180-5.
14. Warhurst DC, Duraisingh MT. Rational use of drugs against Plasmodium falciparum. Trans R Soc Trop Med Hyg 2001; 95:345-6. (Pubitemid 33713093)
15. Mwai L, Kiara SM, Abdirahman A, et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother 2009; 53:5069-73.
16. Sisowath C, Petersen I, Veiga MI, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis 2009; 199:750-7.
17. Sisowath C, Stromberg J, Martensson A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemetherlumefantrine (Coartem). J Infect Dis 2005; 191:1014-7.
18. Duraisingh MT, Roper C, Walliker D, Warhurst DC. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol 2000; 36:955-61. (Pubitemid 30326539)
19. Rodrigues A, Schellenberg JA, Kofoed PE, Aaby P, Greenwood B. Changing pattern of malaria in Bissau, Guinea Bissau. Trop Med Int Health 2008; 13:410-7.
20. Blessborn D, Romsing S, Annerberg A, et al. Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. J Pharm Biomed Anal 2007; 45:282-7.
21. Lindegårdh N, Forslund M, Green MD, Kaneko A, Bergqvist Y. Automated solid-phase extraction for determination of amodiaquine, chloroquine and metabolites in capillary blood on sampling paper by liquid chromatography. Chromatographia 2002: 5-12. (Pubitemid 34095147)
22. WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva, world Health Organization 2007.
23. Djimde A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001; 344:257-63. (Pubitemid 32108530)
24. Veiga MI, Ferreira PE, Bjorkman A, Gil JP. Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum. Mol Cell Probes 2006; 20:100-4. (Pubitemid 43343722)
25. WHO. Guidelines for the treatment of malaria 2006.
26. Zongo I, Dorsey G, Rouamba N, et al. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 2007; 369:491-8. (Pubitemid 46223467)
27. Sagara I, Dicko A, Djimde A, et al. A randomized trial of artesunatesulfamethoxypyrazine- pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg 2006; 75:630-6. (Pubitemid 46941266)
28. Piola P, Fogg C, Bajunirwe F, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005; 365:1467-73. (Pubitemid 40591691)
29. Mwai L, Kiara SM, Abdirahman A, et al. In vitro activity of piperaquine, lumefantrine and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in Pfcrt and Pfmdr1. Antimicrob Agents Chemother 2009; 53:5069-73.
30. Looareesuwan S, White NJ, Chanthavanich P, et al. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br J Clin Pharmacol 1986; 22:31-6. (Pubitemid 17177201)
31. Smith ER, Klein-Schwartz W. Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med 2005; 28:437-43. (Pubitemid 40523693)
32. White NJ, Miller KD, Churchill FC, et al. Chloroquine treatment of severe malaria in children: pharmacokinetics, toxicity, and new dosage recommendations. N Engl J Med 1988; 319:1493-500. (Pubitemid 19003407)
33. Kofoed PE, Co F, Johansson P, et al. Treatment of uncomplicated malaria in children in Guinea-Bissau with chloroquine, quinine, and sulfadoxine- pyrimethamine. Trans R Soc Trop Med Hyg 2002; 96:304-9. (Pubitemid 34785071)
34. van Vugt M, Brockman A, Gemperli B, et al. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 1998; 42:135-9. (Pubitemid 28053339)
35. Wootton JC, Feng X, Ferdig MT, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002; 418:320-3. (Pubitemid 34790681)
36. Ariey F, Fandeur T, Durand R, et al. Invasion of Africa by a single pfcrt allele of South East Asian type. Malar J 2006; 5:34.
37. Martin RE, Marchetti RV, Cowan AI, Howitt SM, Broer S, Kirk K. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 2009; 325:1680-2.
38. Sanchez CP, Rohrbach P, McLean JE, Fidock DA, Stein WD, Lanzer M. Differences in trans-stimulated chloroquine efflux kinetics are linked to pfcrt in Plasmodium falciparum. Mol Microbiol 2007; 64:407-20. (Pubitemid 46632624)
39. Pussard E, Lepers JP, Clavier F, et al. Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated plasmodium falciparum malaria. Antimicrob Agents Chemother 1991; 35:406-9.
40. Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple firstline therapies against malaria. Proc Natl Acad Sci U S A 2008; 105:14216-21.